VX-A903-2

VX-A903-2 is a discovery-stage bispecific T-cell engager (BiTAC-TCE) being developed by VERAXA Biotech for the treatment of solid tumors, including lung cancer, colon cancer, and pancreatic cancer. The drug candidate is part of VERAXA's proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, which is designed to create next-generation cancer therapies with improved safety and efficacy profiles. VX-A903-2 functions by simultaneously binding to a tumor-associated antigen and the CD3 receptor on T cells, thereby recruiting and activating T cells to induce targeted cytotoxicity against tumor cells. As of the current pipeline information, the specific tumor-associated targets for VX-A903-2 have not been publicly disclosed.